澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

IMMUTEP LTD

0.046

-0.001-2.13%

成交量：1,061.68万

成交额：48.67万

市值：6,779.12万

市盈率：-0.80

高：0.047

开：0.045

低：0.045

收：0.047

52周最高：0.470

52周最低：0.028

股本：14.74亿

流通股本：12.28亿

量比：0.33

换手率：0.86%

股息：- -

股息率：- -

每股收益(TTM):-0.057

每股收益(LYR):-0.042

净资产收益率：-61.85%

总资产收益率：-32.10%

市净率：0.69

市盈率(LYR):-1.09

数据加载中...

总览公司新闻资讯公告

BUZZ--美股走势-Kyivstar 集团、应用材料公司、泰沃基因生物公司

IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果

Immutep与Dr. Reddy's达成战略合作推广创新肿瘤药物Eftilagimod Alfa

IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利

IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa

IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款

在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤新辅助治疗中的主要终点达成

IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展

Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IMM.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.046,"timestamp":1774501920000,"preClose":0.047,"halted":0,"volume":10616797,"delay":0,"changeRate":-0.02127659574468087,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"未开盘","change":-0.001,"latestTime":"03-26 16:12:00 AEDT","open":0.045,"high":0.047,"low":0.045,"amount":486711,"amplitude":0.042553,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1774566000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.047,"openAndCloseTimeList":[[1774479600000,1774501200000]],"volumeRatio":0.33443068300784623,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.047,"auctionPrice":0.046,"auctionVolume":1341241,"auction":3,"marketStatus":"盘后竞价","timestamp":1774501805581}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-32.10%","roe":"-61.85%","lyrEps":-0.042199,"volumeRatio":0.33443068300784623,"shares":1473721306,"dividePrice":0,"high":0.047,"amplitude":0.042553,"preClose":0.047,"low":0.045,"week52Low":0.028,"pbRate":"0.69","psRate":"8.56","week52High":0.47,"institutionHeld":0,"latestPrice":0.046,"eps":-0.057294,"divideRate":0,"volume":10616797,"delay":0,"ttmEps":-0.057294,"open":0.045,"prevYearClose":0.415,"prevWeekClose":0.05,"prevMonthClose":0.385,"prevQuarterClose":0.415,"fiveDayClose":0.051,"twentyDayClose":0.395,"sixtyDayClose":0.43,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619114050","title":"BUZZ--美股走势-Kyivstar 集团、应用材料公司、泰沃基因生物公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114050","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114050?lang=zh_cn&edition=fundamental","pubTime":"2026-03-14 01:55","pubTimestamp":1773424551,"startTime":"0","endTime":"0","summary":"标普500指数.SPX下跌0.27%，报6,654.55点；纳斯达克综合指数.IXIC下跌0.65%，报22,166.50点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL4S4011HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SANA","CVNY","CCUP","CRCD","ADBG","ULTA","LVWR","CMCT","IMM.AU","CVNA","INMD","AMPY","PODD","SVCO","BIAF","VACH","KLAR","AIFF","VEON","KYIV","BW","OFRM","INDV","CRCA","IBG","KLC","AMAT","FITB","PAR","CVNX","CRVS","TVGN","SDHC","ESQ","CRCO","WDCX","ISPC","ARES","HBAN","DOUG","RJF","ICRC"],"gpt_icon":1},{"id":"1132253135","title":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1173503970","title":"Immutep与Dr. Reddy's达成战略合作 推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1192332602","title":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1192332602","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192332602?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 15:30","pubTimestamp":1765179011,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1136653615","title":"在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤新辅助治疗中的主要终点达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1136653615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136653615?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 20:01","pubTimestamp":1760961701,"startTime":"0","endTime":"0","summary":"在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤的新辅助治疗中的主要终点达成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1137674400","title":"IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1137674400","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137674400?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 20:00","pubTimestamp":1760011230,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1124383017","title":"Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=1124383017","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124383017?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 20:02","pubTimestamp":1758542533,"startTime":"0","endTime":"0","summary":"Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}